ELMD vs LUNG vs NVCR vs ATRC

For growth investors, Electromed, Inc.

(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus 8. 0% for Pulmonx Corporation (LUNG). Electromed, Inc. (ELMD) offers the better valuation at 31. 2x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Electromed, Inc.

is actually cheaper at 24. 4x.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +178. 1%, compared to -97. 0% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: ELMD returned +482. 6% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AtriCure, Inc.

(ATRC) is the lower-risk stock at 1. 03β versus Pulmonx Corporation's 2. 36β — meaning LUNG is approximately 130% more volatile than ATRC relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Electromed, Inc.

(ELMD) is pulling ahead at 17. 0% versus 8. 0% for Pulmonx Corporation (LUNG). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to 7. 6% for Pulmonx Corporation. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Electromed, Inc.

(ELMD) is the more profitable company, earning 11. 8% net margin versus -59. 7% for Pulmonx Corporation — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Electromed, Inc.

(ELMD) trades at 24. 4x forward P/E versus 370. 7x for AtriCure, Inc. — 346. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Electromed, Inc.

(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +482. 6% 10Y return). Pulmonx Corporation (LUNG) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +482. 6%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELMD is a small-cap high-growth stock; LUNG is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.